Apellis Pharmaceuticals, Inc.
APLSDelisted May 14, 2026- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001492422
Apellis Pharmaceuticals, Inc. was delisted on May 14, 2026; its insiders filed their last Form 4 on May 14, 2026; 324 institutions reported holding it in 13F filings for Q1 2026, worth $5.56B in total; Soros Fund Management was the only superinvestor holding it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Oct 8, 2026, 1:18 PM ET
Revenue flow, FY2025
Where the revenue went in FY2025, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K/A | 10-K | 10-K |
| Reported | Jan 12, 2026 | Jan 13, 2025 | Jan 8, 2024 | – | Jan 10, 2022 |
| Revenue | $1.00B | $781.4M | $396.6M | $75.4M | $66.6M |
| Operating expenses | $948.4M | $946.3M | $913.7M | $670.0M | $602.8M |
| Research and development | $295.9M | $327.6M | $354.4M | $387.2M | $345.9M |
| Selling, general and administrative | $550.3M | $501.1M | $500.8M | $277.2M | $176.8M |
| Operating income | $55.4M | -$165.0M | -$517.1M | -$594.6M | -$536.3M |
| Income tax | $1.72M | $1.16M | $2.13M | $669.0K | $352.0K |
| Net income | $22.4M | -$197.9M | -$528.6M | -$652.2M | -$746.4M |
| EPS, basic | $0.18 | $-1.60 | $-4.45 | $-6.15 | – |
| EPS, diluted | $0.20 | $-1.60 | $-4.45 | $-6.15 | – |
| Weighted shares, basic | 126.1M | 123.9M | 118.7M | 106.1M | – |
| Weighted shares, diluted | 129.9M | 123.9M | 118.7M | 106.1M | – |
| Margins and growth | |||||
| Operating margin | 5.5% | -21.1% | -130.4% | -788.4% | -805.7% |
| Net margin | 2.2% | -25.3% | -133.3% | -864.7% | -1121.3% |
| Revenue growth, year over year | +28.5% | +97.0% | +425.8% | +13.3% | −73.4% |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K/A | 10-K | 10-K |
| Reported | Jan 12, 2026 | Jan 13, 2025 | Jan 8, 2024 | – | Jan 10, 2022 |
| Cash and equivalents | $466.2M | $411.3M | $351.2M | $551.8M | $640.2M |
| Short-term investments | – | – | – | – | $60.4M |
| Accounts receivable | $366.2M | $264.9M | $206.4M | $7.73M | $10.1M |
| Inventory | $142.6M | $81.4M | $146.4M | $85.7M | $16.3M |
| Total current assets | $1.01B | $789.0M | $766.3M | $719.5M | $824.0M |
| Property, plant and equipment | $1.71M | $2.95M | $4.34M | $6.15M | $6.18M |
| Total assets | $1.08B | $885.1M | $788.7M | $760.2M | $881.8M |
| Accounts payable | $56.8M | $38.6M | $37.5M | $37.3M | $16.9M |
| Total current liabilities | $323.6M | $185.5M | $247.6M | $167.6M | $131.8M |
| Long-term debt | – | – | $93.0M | $92.7M | – |
| Total liabilities | $705.1M | $656.5M | $594.2M | $590.3M | $683.1M |
| Shareholders' equity | $370.1M | $228.5M | $194.5M | $169.9M | $198.7M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K/A | 10-K | 10-K |
| Reported | Jan 12, 2026 | Jan 13, 2025 | Jan 8, 2024 | – | Jan 10, 2022 |
| Operating cash flow | $45.3M | -$87.9M | -$594.7M | -$513.7M | -$563.1M |
| Capital expenditures | $313.0K | $403.0K | $773.0K | $1.52M | $1.10M |
| Free cash flow | $45.0M | -$88.3M | -$595.5M | -$515.3M | -$564.2M |
| Stock-based compensation | $104.0M | $114.1M | $105.9M | $91.1M | $70.7M |
| Investing cash flow | -$313.0K | -$403.0K | -$674.0K | $59.9M | $247.6M |
| Financing cash flow | $8.88M | $149.2M | $394.5M | $365.7M | $392.2M |
| Net change in cash | $55.1M | $60.3M | -$200.8M | -$88.7M | $74.7M |
| Ratio | |||||
| Stock-based compensation, % of revenue | 10.4% | 14.6% | 26.7% | 120.8% | 106.2% |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Apr 30, 2026 | 128.0M | +1.9% | SEC |
| Apr 21, 2026 | 128.0M | +1.9% | SEC |
| Feb 17, 2026 | 127.8M | +1.8% | SEC |
| Oct 23, 2025 | 126.5M | +1.7% | SEC |
| Jul 24, 2025 | 126.3M | +3.7% | SEC |
| Apr 30, 2025 | 125.7M | +3.6% | SEC |
| Feb 19, 2025 | 125.5M | +4.1% | SEC |
| Oct 29, 2024 | 124.4M | +5.0% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.